



## DeuteRx Meets Its Tight Deadline Using Rilas Capabilities

---

DeuteRx is a research and development biotechnology company working to improve small molecule drugs and drug candidates. Our research is based on “chiral - switching” which is when an exchangeable hydrogen is replaced with deuterium in the chiral center of the compound.

As a unique company that works closely with our strategic partners, Rilas Technologies, Inc has proven to be one of our most trusted collaborators. We have been working with Rilas for a number of years as our go-to company for all of our chiral separation needs.

A few months ago though, Rilas came through for us in a very important way. We were quickly approaching a patent deadline with one of our new deuterated compounds, and we still had a final bit of testing left to do. Both a very clean chiral separation of the compound and a stability test of one of the separated enantiomers were needed to complete the application. We sent Rilas the compound and within a week of its arrival Rilas was able to separate the enantiomers, dry the samples, final QC the individual enantiomers, and run the 24 hour stability test. The dedication of the Rilas staff and the quality of the results were critical components in allowing us to submit our patent application on time.

- Sheila DeWitt, PhD  
*President & CEO of DeuteRx*

